Skip to main content
Premium Trial:

Request an Annual Quote

LabCorp Completes Acquisition of Orchid Cellmark

NEW YORK (GenomeWeb News) – Laboratory Corporation of America today said it has completed its $85.4 million buy of Orchid Cellmark.

As of 4 p.m., EST, Dec. 15, the expiration of a subsequent offering period, stockholders of Orchid had tendered an additional 217,184 shares of Orchid's common stock during the subsequent offering period, the depositary for the tender offer advised LabCorp. The number of shares acquired during this period combined with the number of shares accepted for payment during the initial offering period represents an aggregate of 87.2 percent of Orchid's currently outstanding shares.

Orchid is now a subsidiary of LabCorp and its shares will stop trading on Nasdaq.

The deal was announced in April but was delayed several times as the US Federal Trade Commission requested additional information.

In early morning trading, shares of LabCorp on the New York Stock Exchange were up 1 percent to $82.27.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.